OCI invites pharmaceutical supply chain actors into its Early Adopter Program to trial the industry’s first compliance solution for U.S. DSCSA Authorized Trading Partner authentication. The launch of the program now makes the industry’s first functional, scalable solution widely available enabling U.S. supply chain actors to become DSCSA-compliant well ahead of the deadline.

OCI, a collaborative industry effort, issued a call for the pharmaceutical industry to align on core standards around Authorized Trading Partner (ATP) authentication in compliance with the Drug Supply Chain Security Act (DSCSA). Formed by a group of trading partners, solution providers, and standards organizations, OCI is charting the course for ATP interoperability by 2023.